Ja Hyeon Ku

机构：Seoul National University Hospital · ORCID：0000-0002-0391-2342

发表论文 549 篇 · 总被引 10051 次 · h-index 47

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 123)
• Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial (2025 · Nature Medicine · 被引 89)
• Fully automated segmentation and classification of renal tumors on CT scans via machine learning (2025 · BMC Cancer · 被引 19)
• TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial (2025 · The Lancet Oncology · 被引 16)
• Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. (2025 · Journal of Clinical Oncology · 被引 9)
• Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review (2025 · Clinical Genitourinary Cancer · 被引 6)